NCT03245762View on ClinicalTrials.gov

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

January 4, 2018

Study Completion Date

January 4, 2018

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Oxytocin

4 IU/day of oxytocin administered via nasal spray device each morning.

DRUG

Placebo

4 IU/day of placebo administered via nasal spray device each morning

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
collaborator

Prader-Willi Syndrome Association

OTHER

lead

University of Florida

OTHER

NCT03245762 - Intranasal Oxytocin for Infants With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter